Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1745-1751

  Denardo, Sally J ^a,d   O'Grady, Lois F ^a   Richman, Carol M ^a   Goldstein, Desiree S ^a   O'Donnell, Robert T ^a   Denardo, Diane A ^a   Kroger, Linda A ^a   Lamborn, Kathleen R ^b   Hellström, Karl Erik ^c   Hellström, Ingegerd ^c   Denardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Oncogen   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

Antibody; Breast cancer; ChL6; L6; Radioimmunotherapy

Indexed keywords

COMPLEMENT; CYTOKINE; IODINE 131; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANTIBODY TITER; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; EFFECTOR CELL; FEMALE; HUMAN; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 0030901830     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wright C, Angus B, Nicholson S, Sainsbury JRC Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erb B-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-2090, 1989.
2. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harns AL: Epidermal growth factor status as predictor of early recurrence of and death from breast cancer. Lancet 1(8547): 1398-1402, 1987.
3. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994.
4. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi V: Ten years experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treatm 5: 95-115, 1985.
5. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cells support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37-44, 1994.
6. Klumpp TR, Mangan KF, Glenn LD, Macdonald JS: Phase II pilot study of high-dose busulfan and CY followed by autotogous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 11: 337-339, 1993.
7. Goodman GE, Hellström I. Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellström KE: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 8: 1083-1092, 1990.
8. Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J, Hellstrom KE: Phase I trial of chimeric (humanmouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36: 267-273, 1993.
9. Oettgen HF, Old LJ: The history of cancer immunotherapy In: Biologic Therapy of Cancer (DeVita VT Jr, Hellman S. Rosenberg SA, eds). Philadelphia, PA, Lippincott, 1991, pp 87-119.
10. Mittelman A, Che T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z, et al: Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. [erratum J Clin Invest 87: 757, 1991]. J Clin Invest 86: 2136-2144, 1990.
11. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, Peng JS, McGahan JP: Treatment of a patient with B cell lymphoma by 1-131 Lym-1 monoclonal antibodies. Int J Biol Markers 2: 49-53, 1987.
12. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329: 459-465, 1993.
13. Caron PC, Scheinberg DA: Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymph 11: 1-6, 1993.
14. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73: 1425-1432, 1994.
15. 90Y-Anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma. Int J Radiat Oncol Biol Phys 32: 215, 1995.
16. DeNardo SJ, DeNardo GL, O'Grady LF, Levy NB, Mills SL, Macey DJ, McGahan JP, Miller CH, Epstein AL: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using 1-131 -Lym-1 monoclonal antibody. Antib Immunoconjug Radiopharm 1: 17-33, 1988.
17. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94: 297-312, 1993.
18. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72: 2101-2114, 1983.
19. Begent RH, Ledermann JA, Green AJ, Bagshowe KD, Riggs SJ, Seagle F, Keep PA, Adam T, Dale RG, Glaser MG: Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 60: 406-412, 1989.
20. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, Schochat D, Wheeler RH, LoBuglio AF: Phase I trial of iodine-131 -chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 33: 23-29, 1992.
21. 131I-CC49 in colorectal cancer. Cancer 73: 1057-1066, 1994.
22. DeNardo, SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellström I, Hellström KE: Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Nucl Med Biol 18: 621-631, 1991.
23. 131L6 chimeric monoclonal antibody. Inter J Biol Markers 6: 221-230, 1991.
24. DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Hellström I, Hellström KE, DeNardo GL: The biologic window for ChL6 radioimmunotherapy. Cancer 73: 1023-1032, 1994.
25. Hellström I, Horn D, Linsley P, Brown JP, Brankovan V, Hellström KE: Monoclonal antibodies raised against human lung carcinomas. Cancer Res 46: 3917-3923, 1986.
26. Hellström I, Beaumier PL, Hellström KE: Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA 83: 7059-7063, 1986.
27. Marken JS, Schieven GL, Hellström I, Hellström KE, Aruffo A: Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci USA 89: 3503-3507, 1992.
28. Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo, GL, Hellström I, Hellström KE: Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric ChL6 antibody. Antib Immunoconjug Radiopharm 5: 81-95, 1992.
29. Fell HP, Gayle MA, Yelton D, Lipsich L, Schieven GL, Marken JS, Aruffo A, Hellström KE, Hellström I, Bajorath J: Chimeric L6 antitumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 267: 15552-15558, 1992.
30. DeNardo SJ, DeNardo GL, Peng J-S: Pharmaceutical quality control for radiolabeled monoclonal antibodies and their fragments. Am J Physiol Imag 4: 39-44, 1989.
31. Howell LP, DeNardo SJ, Levy NB, Lund J, DeNardo GL: Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 10: 129-135, 1995.
32. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL: Quantitative pharmacokinetics of radiolabeled monoclonal antibodies in patients. In: Radiolabeled Monoclonal Antibodies for Imaging and Therapy (Srivastava SC, ed). New York, Plenum Press,1988, pp 293-310.
33. Snyder WS, Ford WR, Warner GG: 'S' absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet 11. Society of Nuclear Medicine, NY, 1975.
34. Siegel JA, Wessels BW, Watson EE, Fisher DR, Buchsbaum DJ, Order SE, Brill AB, Kwok CS, Stickney DR, Echerman KF, Stabin MG, Vriesendorp HM, Bradley EN, Badger CC: Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib Immunoconjug Radiopharm 3: 213-233, 1990.
35. 131I-Lym-1 in patients with Bcell malignancies. Nucl Med Comm 14: 587-595, 1993.
36. Macey DJ, DeNardo SJ, DeNardo GL, Goodnight JK, Unger MW: Uptake of In-111 labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am J Physiol Imaging. 3: 1-6, 1988.
37. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. Antibody responses to macrocycles with lymphoma. J Nucl Med 37: 451-456, 1996.